David Hoyt
Family Medicine · Mercer, PANPI 1245209469
Payments from drug & device makers
Across 311 payments — averaging $21.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2K
- Novo Nordisk$754
- Lilly USA, LLC$746
- AbbVie$415
- GSK$413
- Novartis$380
- plus $2K from 31 others
What the payments were for
- Speaking & faculty fees$1,25019%
- Food & beverage$5,42880%
- Education$771%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 43 | $1,736 |
| Novo Nordisk | 45 | $754 |
| Lilly USA, LLC | 30 | $746 |
| AbbVie(2 entities) | 31 | $415 |
| GSK | 23 | $413 |
| Novartis | 20 | $380 |
| AstraZeneca | 18 | $378 |
| Amarin Pharma, Inc. | 12 | $220 |
| Johnson & Johnson | 14 | $219 |
| Bayer | 7 | $201 |
| E.r. Squibb & Sons, L.L.C. | 9 | $190 |
| Boehringer Ingelheim | 7 | $147 |
| Inari Medical, Inc. | 5 | $127 |
| Amgen | 6 | $123 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $82 |
| Merck | 4 | $57 |
| Daiichi Sankyo Inc. | 2 | $51 |
| Sanofi-aventis U.S. LLC | 3 | $48 |
| Exact Sciences | 3 | $47 |
| Shield Therapeutics Inc | 2 | $41 |
| Kowa Pharmaceuticals America, Inc. | 2 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $38 |
| Boston Scientific | 2 | $35 |
| Otsuka America Pharmaceutical, Inc. | 1 | $29 |
| Teva Pharmaceuticals USA, Inc. | 2 | $27 |
| Eisai Inc. | 1 | $24 |
| Vertex | 1 | $21 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Dexcom, Inc. | 1 | $19 |
| Ironwood Pharmaceuticals, Inc | 1 | $17 |
| Bristol Myers Squibb | 1 | $17 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Actelion Pharmaceuticals US, Inc. | 1 | $14 |
| Astellas Pharma US Inc | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,755 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 735 | $466,309 |
| OzempicSemaglutide | 288 | $312,646 |
| MounjaroTirzepatide | 175 | $211,013 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 155 | $136,357 |
| TrulicityDulaglutide | 111 | $136,208 |
| XareltoRivaroxaban | 115 | $105,212 |
| JardianceEmpagliflozin | 134 | $93,599 |
| TradjentaLinagliptin | 88 | $60,648 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 84 | $45,278 |
| RybelsusSemaglutide | 28 | $42,491 |
| FarxigaDapagliflozin Propanediol | 35 | $36,368 |
| EntrestoSacubitril/Valsartan | 33 | $32,316 |
| ActemraTocilizumab | 25 | $30,134 |
| TivicayDolutegravir Sodium | 12 | $26,653 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 161 | $22,690 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $1,736 | $475,193756 claims |
| Novo NordiskOzempic, Rybelsus | $754 | $355,137316 claims |
| Lilly USA, LLCMounjaro, Trulicity | $746 | $347,221286 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $147 | $165,056245 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $413 | $154,808195 claims |
| Johnson & JohnsonXarelto | $219 | $105,212115 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $378 | $53,28862 claims |
| NovartisEntresto | $380 | $32,31633 claims |
| AbbVieLinzess | $415 | $10,63314 claims |
| MerckJanuvia | $57 | $10,34116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Mercer
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.